Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor
Endeavor's Hedgehog pathway inhibitor taladegib (ENV-101) met the ppFVC primary endpoint in the phase 2b WHISTLE-PF trial in IPF, and the company plans to advance to phase 3. The trial enrolled 213 patients across 74 centers in 14 countries, with results announced on 2026-10-08. The mechanism differs from existing pirfenidone and nintedanib; the poster sees it as a potential threat to current IPF therapies, but phase 2b success does not guarantee phase 3 or approval.
An r/biotech post (u/Dwarvling) reported that Endeavor's Hedgehog pathway inhibitor taladegib (ENV-101) met its primary endpoint (ppFVC improvement) in the WHISTLE-PF Phase 2b for IPF, posing a potential threat to existing IPF therapies (such as pirfenidone/nintedanib), with the company planning to advance to Phase 3. The post has no comments. Factually, the WHISTLE-PF Phase 2b (announced 2026-10-08, 213 patients, 74 sites across 14 countries, met the ppFVC primary endpoint with Phase 3 planned) was verified via search (✔); however, 'threatening incumbents' is the author's market judgment, and Phase 2b success does not mean Phase 3 success or approval.
Checked ✔ (WHISTLE-PF Phase 2b, ENV-101/taladegib, 213 patients, met ppFVC primary endpoint, Phase 3 planned, verified via search; 'threat to incumbents' is a market judgment)
Hedgehog pathway inhibitor taladegib met the ppFVC primary endpoint in IPF phase 2b, offering a new-mechanism candidate beyond pirfenidone and nintedanib.
Source: Reddit